C4 Therapeutics Inc

10-Year Study

CCCC.US · Healthcare · US · Common Stock

Executive Summary: C4 Therapeutics Inc has compounded at -32.3% annually over the last 10 years, with a maximum drawdown of 97.2% and an annualized volatility of 98.8%.

1Y CAGR
+150.3%
3Y CAGR
-5.2%
5Y CAGR
-40.4%
10Y CAGR
-32.3%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
97.2%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.14
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.39
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
135.1%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +51.8%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2022 · -81.7%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
17%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-0.542.1-2.610.3————————51.8%
2025-3.6-21.9-41.02.5-23.814.443.426.8-14.617.63.8-29.5-46.9%
20249.477.7-25.6-22.9-20.6-7.645.0-5.7-9.8-6.5-14.6-20.9-36.3%
202332.0-32.3-40.4-3.812.3-18.941.5-25.4-35.9-19.99.4246.6-4.2%
2022-24.1-8.28.2-64.7-15.33.927.94.6-13.09.7-10.9-31.2-81.7%
20219.018.8-13.8-10.511.62.414.0-7.011.3-0.6-16.4-13.3-2.8%
2020——————————38.2-3.133.9%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 98.8%. The dominant macroeconomic risk driver is VTI.US, accounting for 25.8% of variance. Idiosyncratic stock-specific factors contribute 46.9%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2020-10-0110000
2020-11-0113818.182126440184
2020-12-0113385.859017420296
2021-01-0114593.938962377684
2021-02-0117341.413401594065
2021-03-0114945.455223622948
2021-04-0113373.736757220644
2021-05-0114929.293237551294
2021-06-0115288.888950540562
2021-07-0117430.302783696337
2021-08-0116214.141845703125
2021-09-0118052.525375828598
2021-10-0117947.47400765467
2021-11-0114997.979366418085
2021-12-0113010.101318359375
2022-01-019870.707194010416
2022-02-019062.626385929609
2022-03-019802.020294497712
2022-04-013462.626139322917
2022-05-012933.333425810843
2022-06-013046.4646310517287
2022-07-013894.949633665759
2022-08-014072.727241901436
2022-09-013543.4345283893626
2022-10-013886.868640629932
2022-11-013462.626139322917
2022-12-012383.8384223706794
2023-01-013147.474732061829
2023-02-012129.29292158647
2023-03-011268.686911072394
2023-04-011220.2020124955611
2023-05-011369.697012082495
2023-06-011111.111111111111
2023-07-011571.717214102697
2023-08-011171.7172102494674
2023-09-01751.5151572949959
2023-10-01602.0202058734316
2023-11-01658.5858566592439
2023-12-012282.8283213605787
2024-01-012496.969627611565
2024-02-014436.363451408618
2024-03-013301.0101318359375
2024-04-012545.4546225191366
2024-05-012020.20202020202
2024-06-011866.666620427912
2024-07-012707.070630006116
2024-08-012553.5354228934857
2024-09-012303.030225965712
2024-10-012153.535322709517
2024-11-011838.3839154484297
2024-12-011454.545416013159
2025-01-011402.0202135798907
2025-02-011094.9495103624133
2025-03-01646.4646560977204
2025-04-01662.6262568464183
2025-05-01505.050505050505
2025-06-01577.7777565850153
2025-07-01828.2828090166805
2025-08-011050.505011972755
2025-09-01896.9697085293857
2025-10-011054.5454121599294
2025-11-011094.9495103624133
2025-12-01771.7171582308682
2026-01-01767.6767580436939
2026-02-011090.909090909091
2026-03-011062.6262626262626
2026-04-011171.7171717171716
Annual Return Matrix
YearAnnual Return
2021-0.028071242837079957
2022-0.8167701877150876
2023-0.04237288067101819
2024-0.3628318860411537
2025-0.4694444396613555
20260.5183246338636398
Total Factor Risk
0.9877523878865005
VTI.US Exposure
0.2576936464702773
VEA.US Exposure
0.0059908446631482
VWO.US Exposure
0.0033170551152615873
QQQ.US Exposure
-0.1413134622182389
VTV.US Exposure
-0.07714972056867979
IJR.US Exposure
0.1964034904150736
QUAL.US Exposure
0.16601107347279168
SHV.US Exposure
0.042676089166182006
TLT.US Exposure
0.11069059168366611
LQD.US Exposure
-0.02474451179883512
HYG.US Exposure
0.006845299517885433
GLD.US Exposure
0.008419494001985871
USO.US Exposure
0.0002338007346609379
VNQ.US Exposure
-0.009992370452476052
BTC-USD.CC Exposure
-0.003776797404860155
CPER.US Exposure
-0.004700097411218961
VIX.INDX Exposure
-0.02352332165136932
UUP.US Exposure
0.022145568525707326
TIP.US Exposure
-0.003991790378963833
Idiosyncratic Exposure
0.4687651181180019
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
98.8%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$275.2M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+13.3%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+20.9%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
19.2% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
2.86
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is C4 Therapeutics Inc a high-risk investment?

C4 Therapeutics Inc (CCCC.US) has an annualized volatility of 98.8% and experienced a maximum drawdown of 97.2% over the last 10 years. Its primary macro risk driver is VTI.US.

What is the 10-year return of CCCC.US?

Over the past 10 years, CCCC.US has generated a Compound Annual Growth Rate (CAGR) of -32.3%. It has had a positive return in 17% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on C4 Therapeutics Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest